Lv7
3770 积分 2021-08-25 加入
[Consensus on clinical diagnosis and treatment of breast cancer with low expression and ultralow expression of HER-2 (2025 edition)]
1个月前
已完结
Prediction of survival after de-escalated neoadjuvant therapy in HER2+ early breast cancer: A pooled analysis of three WSG trials
2个月前
已关闭
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
3个月前
已完结
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
3个月前
已完结
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01
3个月前
已完结
[Chinese expert consensus on the management of clinical pathway and adverse events of trastuzumab deruxtecan (2024 edition)]
6个月前
已完结
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer
8个月前
已完结
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
10个月前
已完结
皖公网安备34019202002308
